Phase I
The interim analysis demonstrated that two doses of the vaccine ranging from 2 micrograms to 12 micrograms per dose, given 28 days apart, were safe, with no vaccine-related serious adverse events.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 10, 2020.
It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look.
There was a handful of positive clinical trial news reported today. Here’s a look.
South San Francisco-based Allogene Therapeutics released some early data from its Phase I UNIVERSAL clinical trial of ALLO-715 for relapsed/refractory multiple myeloma.
Aptevo is a clinical-stage biotech company developing novel therapeutics built on its proprietary platform ADAPTIR™technology which is modular and includes bispecific molecules that recognize and bind to two unique target antigens simultaneously.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
Regeneron announced on Friday that it is pausing dosing of garetosmab (REGN2477), an investigational therapy, in the Phase I LUMINA-1 trial.
Newly announced results of a Phase I dose-escalation study show CureVac’s COVID-19 vaccine candidate, CVnCoV, generates noticeable immune responses in healthy volunteers.
It was a particularly busy week for announcements about clinical trials, both related to COVID-19 and everything else. Here’s a look.
PRESS RELEASES